

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

216165Orig1s000

PROPRIETARY NAME REVIEW(S)

PROPRIETARY NAME REVIEW

Division of Medication Error Prevention and Analysis 1 (DMEPA 1)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	September 11, 2023
Application Type and Number:	IND 122269 and NDA 216165
Product Name and Strength:	Exblifep (cefepime and enmetazobactam) for Injection, 2.5 grams per vial (2 grams cefepime and 0.5 grams enmetazobactam per vial)
Product Type:	Multiple Ingredient Product
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Allegra Therapeutics SAS (Allegra)
PNR ID #:	2023-1044724539 and 2023-1044725200
DMEPA 1 Safety Evaluator:	Deborah Myers, RPh, MBA
DMEPA 1 Team Leader:	Valerie S. Vaughan, PharmD
DMEPA 1 Director:	Mishale Mistry, PharmD, MPH

Contents

1	INTRODUCTION	1
1.1	Regulatory History.....	1
1.2	Product Information.....	1
2	RESULTS.....	2
2.1	Misbranding Assessment	2
2.2	Safety Assessment	2
3	CONCLUSION	4
3.1	Comments to Allecra Therapeutics SAS	4
4	REFERENCES	5
	APPENDICES	6

1 INTRODUCTION

This review evaluates the proposed proprietary name, Exblifep, from a safety and misbranding perspective. The sources and methods used to evaluate the proposed proprietary name are outlined in the reference section and Appendix A, respectively. Allecra submitted an external name study, conducted by (b) (4), for this proposed proprietary name.

1.1 REGULATORY HISTORY

Allecra submitted the proposed proprietary name, Exblifep, for review under IND 122269 on April 12, 2022. Subsequently, Allecra submitted the proposed proprietary name, Exblifep, for review under NDA 216165 on June 22, 2023.

This review evaluates the proposed proprietary name, Exblifep, under both IND 122269 and NDA 216165.

1.2 PRODUCT INFORMATION

The following product information is provided in the proprietary name submission received on June 22, 2023, and amendment received on June 23, 2023.

- Intended Pronunciation: X blee fep
- Active Ingredients: cefepime and enmetazobactam
- Indication of Use: for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis, (b) (4) caused by designated susceptible (b) (4)
- Route of Administration: intravenous infusion
- Dosage Form: for Injection
- Strength: 2.5 grams per vial (2 grams cefepime and 0.5 grams enmetazobactam per vial)
- Dose and Frequency: 2.5 grams (cefepime 2 grams and enmetazobactam 0.5 grams) every 8 hours for 7 to 14 days, in patients with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m².

Dosage adjustment is recommended in patients with renal impairment who have an eGFR less than 60 mL/min/ 1.73m² (see table below).

eGFR ^a (mL/min/ 1.73m ²)	Recommended Dosage Regimen for EXBLIFEP (cefepime and enmetazobactam) ^{b,c}	Dosing Interval
30 to 59	EXBLIFEP 1.25 grams (cefepime 1 gram and enmetazobactam 0.25 grams)	Every 8 hours
(b) (4)		

^a As calculated using the Modification of Diet in Renal Disease (MDRD) formula; ^b All doses of EXBLIFEP are administered intravenously over 2 hours; ^c The total duration of treatment is for 7 to 14 days; ^d On hemodialysis days, doses should be administered after a hemodialysis session.

- How Supplied: as a white to off-white sterile powder for constitution in single dose, clear glass vials sealed with a rubber stopper (not made with natural rubber latex) and an aluminum overseal. Each vial is supplied in cartons of 10 vials.
- Storage: Prior to reconstitution: Store vials under refrigeration at 2°C to 8°C (36°F to 46°F).

2 RESULTS

The following sections provide information obtained and considered in the overall evaluation of the proposed proprietary name, Exblifep.

2.1 MISBRANDING ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined that Exblifep would not misbrand the proposed product. The Division of Medication Error Prevention and Analysis 1 (DMEPA 1) concurred with the findings of OPDP's assessment for Exblifep. The Division of Anti-Infectives (DAI) concurred with the findings of OPDP's assessment for Exblifep.

2.2 SAFETY ASSESSMENT

The following aspects were considered in the safety evaluation of the proposed proprietary name, Exblifep.

2.2.1 United States Adopted Names (USAN) Search

There is no USAN stem present in the proposed proprietary name^a.

2.2.2 Components of the Proposed Proprietary Name

Allegra indicated in their submission that the proposed proprietary name, Exblifep, is derived from the "Extended Spectrum Beta Lactamase Inhibitor and Cefepime (FEP)." This proprietary name is comprised of a single word which includes the letter string, 'Ex-, ' a medical abbreviation for the modifier "extra strength." In some circumstances, the incorporation of medical abbreviations in proprietary names can inadvertently be a source of error. For more information see draft guidance, *Best Practices in Developing Proprietary Names for Human Prescription Drug Products*.^b

We considered if the abbreviation, 'ex,' located in the prefix could result in name confusion if it were to be inadvertently interpreted as a modifier or as part of the prescription directions, separate from the proposed proprietary name, Exblifep (e.g., user interprets order as Ex Blifep). Currently, there is no product marketed under the proprietary name, 'Blifep,' or beginning with the letter string, 'blif.' Additionally, we note that the abbreviation, 'ex,' exists in the prefix of the marketed names, Exelderm and Exforge and we are not aware of any medication error reports of

^a USAN stem search conducted on June 29, 2023.

^b Guidance for Industry: Best Practices in Developing Proprietary Names for Human Prescription Drug Products. 2020. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

misinterpretation of the letter string, ‘ex,’ as a modifier or part of the prescription direction to date.

Thus, in this case we do not object to the inclusion of the letter string, ‘ex,’ in the prefix of the proposed proprietary name.

2.2.3 Comments from Other Review Disciplines at Initial Review

On July 18, 2023, the Division of Anti-Infectives (DAI) did not forward any comments or concerns relating to Exblifep at the initial phase of the review.

2.2.4 FDA Name Simulation Studies

Eighty-seven practitioners participated in DMEPA’s prescription studies for Exblifep. The responses did not overlap with any currently marketed products nor did the responses sound or look similar to any currently marketed products or any products in the pipeline.

Appendix B contains the results from the prescription simulation studies.

2.2.5 Phonetic and Orthographic Computer Analysis (POCA) Search Results

Our POCA search^c identified 15 names with a combined phonetic and orthographic score of $\geq 55\%$ or an individual phonetic or orthographic score $\geq 70\%$. These names are included in Table 1 below.

2.2.6 Names Retrieved for Review Organized by Name Pair Similarity

Table 1 lists the number of names retrieved from our POCA search and (b) (4) external study. These name pairs are organized as highly similar, moderately similar or low similarity for further evaluation.

Table 1. Names Retrieved for Review Organized by Name Pair Similarity	
Similarity Category	Number of Names
Highly similar name pair: combined match percentage score $\geq 70\%$	2
Moderately similar name pair: combined match percentage score $\geq 55\%$ to $\leq 69\%$	18
Low similarity name pair: combined match percentage score $\leq 54\%$	22

^c POCA search conducted on June 29, 2023 in version 5.2.

2.2.7 Safety Analysis of Names with Potential Orthographic, Spelling, and Phonetic Similarities

Our analysis of the 42 names contained in Table 1 determined none of the names will pose a risk for confusion with Exblifep as described in Appendices C through H.

2.2.8 Communication of DMEPA's Determination

On September 11, 2023, DMEPA 1 communicated our determination to the Division of Anti-Infectives (DAI).

3 CONCLUSION

The proposed proprietary name, Exblifep, is conditionally acceptable.

If you have any questions or need clarifications, please contact Amy Chung, OSE project manager, at 240-402-4547.

3.1 COMMENTS TO ALLECRA THERAPEUTICS SAS

We have completed our review of the proposed proprietary name, Exblifep, and have concluded that this name is conditionally acceptable.

If any of the proposed product characteristics as stated in your submission, received on June 22, 2023, and amendment received on June 23, 2023, are altered prior to approval of the marketing application, the name must be resubmitted for review.

4 REFERENCES

1. **USAN Stems** (<https://www.ama-assn.org/about/united-states-adopted-names-approved-stems>)

USAN Stems List contains all the recognized USAN stems.

2. **Phonetic and Orthographic Computer Analysis (POCA)**

POCA is a system that FDA designed. As part of the name similarity assessment, POCA is used to evaluate proposed names via a phonetic and orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists that operates in a similar fashion. POCA is publicly accessible.

Drugs@FDA

Drugs@FDA is an FDA Web site that contains most of the drug products approved in the United States since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA-approved *brand name* and *generic drugs*; *therapeutic biological products*, *prescription* and *over-the-counter* human drugs; and *discontinued drugs* (see Drugs @ FDA Glossary of Terms, available at http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm#ther_biological).

RxNorm

RxNorm contains the names of prescription and many OTC drugs available in the United States. RxNorm includes generic and branded:

- Clinical drugs – pharmaceutical products given to (or taken by) a patient with therapeutic or diagnostic intent
- Drug packs – packs that contain multiple drugs, or drugs designed to be administered in a specified sequence

Radiopharmaceuticals, contrast media, food, dietary supplements, and medical devices, such as bandages and crutches, are all out of scope for RxNorm

(<http://www.nlm.nih.gov/research/umls/rxnorm/overview.html>).

Division of Medication Errors Prevention and Analysis proprietary name consultation requests

This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

APPENDICES

Appendix A

FDA's Proprietary Name Risk Assessment evaluates proposed proprietary names for misbranding and safety concerns.

1. **Misbranding Assessment:** For prescription drug products, OPDP assesses the name for misbranding concerns. For over-the-counter (OTC) drug products, the misbranding assessment of the proposed name is conducted by DNDP. OPDP or DNDP evaluates proposed proprietary names to determine if the name is false or misleading, such as by making misrepresentations with respect to safety or efficacy. For example, a fanciful proprietary name may misbrand a product by suggesting that it has some unique effectiveness or composition when it does not (21 CFR 201.10(c)(3)). OPDP or DNDP provides their opinion to DMEPA for consideration in the overall acceptability of the proposed proprietary name.
2. **Safety Assessment:** The safety assessment is conducted by DMEPA, and includes the following:
 - a. Preliminary Assessment: We consider inclusion of USAN stems or other characteristics that when incorporated into a proprietary name may cause or contribute to medication errors (i.e., dosing interval, dosage form/route of administration, medical or product name abbreviations, names that include or suggest the composition of the drug product, etc.) See prescreening checklist below in Table 2*. DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer.^d

^d National Coordinating Council for Medication Error Reporting and Prevention. <https://www.nccmerp.org/about-medication-errors> Last accessed 10/05/2020.

***Table 2- Prescreening Checklist for Proposed Proprietary Name**

	Answer the questions in the checklist below. Affirmative answers to any of these questions indicate a potential area of concern that should be carefully evaluated as described in this guidance.
Y/N	Is the proposed name obviously similar in spelling and pronunciation to other names?
	Proprietary names should not be similar in spelling or pronunciation to proprietary names, established names, or ingredients of other products.
Y/N	Are there inert or inactive ingredients referenced in the proprietary name?
	Proprietary names should not incorporate any reference to an inert or inactive ingredient in a way that might create an impression that the ingredient's value is greater than its true functional role in the formulation (21 CFR 201.10(c)(4)).
Y/N	Does the proprietary name include combinations of active ingredients?
	Proprietary names of fixed combination drug products should not include or suggest the name of one or more, but not all, of its active ingredients (see 21 CFR 201.6(b)).
Y/N	Is there a United States Adopted Name (USAN) stem in the proprietary name?
	Proprietary names should not incorporate a USAN stem in the position that USAN designates for the stem.
Y/N	Is this proprietary name used for another product that does not share at least one common active ingredient?
	Drug products that do not contain at least one common active ingredient should not use the same (root) proprietary name.
Y/N	Is this a proprietary name of a discontinued product?
	Proprietary names should not use the proprietary name of a discontinued product if that discontinued drug product does not contain the same active ingredients.

- b. Phonetic and Orthographic Computer Analysis (POCA): Following the preliminary screening of the proposed proprietary name, DMEPA staff evaluates the proposed name against potentially similar names. In order to identify names with potential similarity to the proposed proprietary name, DMEPA enters the proposed proprietary name in POCA and queries the name against the following drug reference databases, Drugs@FDA, Cerner RxNorm, and names in the review pipeline using a 55% threshold in POCA. DMEPA reviews the combined orthographic and phonetic matches and group the names into one of the following three categories:
- Highly similar pair: combined match percentage score $\geq 70\%$.
 - Moderately similar pair: combined match percentage score $\geq 55\%$ to $\leq 69\%$.

- Low similarity: combined match percentage score $\leq 54\%$.

Using the criteria outlined in the check list (Table 3-5) that corresponds to each of the three categories (highly similar pair, moderately similar pair, and low similarity), DMEPA evaluates the name pairs to determine the acceptability or non-acceptability of a proposed proprietary name. The intent of these checklists is to increase the transparency and predictability of the safety determination of whether a proposed name is vulnerable to confusion from a look-alike or sound-alike perspective. Each bullet below corresponds to the name similarity category cross-references the respective table that addresses criteria that DMEPA uses to determine whether a name presents a safety concern from a look-alike or sound-alike perspective.

- For highly similar names, differences in product characteristics often cannot mitigate the risk of a medication error, including product differences such as strength and dose. Thus, proposed proprietary names that have a combined score of ≥ 70 percent are at risk for a look-alike sound-alike confusion which is an area of concern (See Table 3).
- Moderately similar names are further evaluated to identify the presence of attributes that are known to cause name confusion.
 - Name attributes: We note that the beginning of the drug name plays a significant role in contributing to confusion. Additionally, drug name pairs that start with the same first letter and contain a shared letter string of at least 3 letters in both names are major contributing factor in the confusion of drug names^e. We evaluate all moderately similar names retrieved from POCA to identify the above attributes. These names are further evaluated to identify overlapping or similar strengths or doses.
 - Product attributes: Moderately similar names of products that have overlapping or similar strengths or doses represent an area for concern for FDA. The dose and strength information is often located in close proximity to the drug name itself on prescriptions and medication orders, and the information can be an important factor that either increases or decreases the potential for confusion between similarly named drug pairs. The ability of other product characteristics to mitigate confusion (e.g., route, frequency, dosage form) may be limited when the strength or dose overlaps. DMEPA reviews such names further, to determine whether sufficient differences exist to prevent confusion. (See Table 4).
- Names with low similarity that have no overlap or similarity in strength and dose are generally acceptable (See Table 5) unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.
- c. FDA Prescription Simulation Studies: DMEPA staff also conducts a prescription simulation studies using FDA health care professionals.

^e Shah, M, Merchant, L, Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

Four separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions, verbal pronunciation of the drug name or during computerized provider order entry. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify vulnerability of the proposed name to be misinterpreted by healthcare practitioners during written, verbal, or electronic prescribing.

In order to evaluate the potential for misinterpretation of the proposed proprietary name during written, verbal, or electronic prescribing of the name, written inpatient medication orders, written outpatient prescriptions, verbal orders, and electronic orders are simulated, each consisting of a combination of marketed and unapproved drug products, including the proposed name.

- d. Comments from Other Review Disciplines: DMEPA requests the Office of New Drugs (OND) and/or Office of Generic Drugs (OGD), ONDQA or OBP for their comments or concerns with the proposed proprietary name, ask for any clinical issues that may impact the DMEPA review during the initial phase of the name review. Additionally, when applicable, at the same time DMEPA requests concurrence/non-concurrence with OPDP's decision on the name. The primary Safety Evaluator addresses any comments or concerns in the safety evaluator's assessment.

The OND/OGD Regulatory Division is contacted a second time following our analysis of the proposed proprietary name. At this point, DMEPA conveys their decision to accept or reject the name.

Additionally, other review disciplines opinions such as ONDQA or OBP may be considered depending on the proposed proprietary name.

When provided, DMEPA considers external proprietary name studies conducted by or for the Applicant/Sponsor and incorporates the findings of these studies into the overall risk assessment.

The DMEPA primary reviewer assigned to evaluate the proposed proprietary name is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name.

Table 3. Highly Similar Name Pair Checklist (i.e., combined Orthographic and Phonetic score is $\geq 70\%$).

Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may render the names less likely to confusion, provided that the pair does not share a common strength or dose.			
<u>Orthographic Checklist</u>		<u>Phonetic Checklist</u>	
Y/N	Do the names begin with different first letters? <i>Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.</i>	Y/N	Do the names have different number of syllables?
Y/N	Are the lengths of the names dissimilar* when scripted? <i>*FDA considers the length of names different if the names differ by two or more letters.</i>	Y/N	Do the names have different syllabic stresses?
Y/N	Considering variations in scripting of some letters (such as z and f), is there a different number or placement of upstroke/downstroke letters present in the names?	Y/N	Do the syllables have different phonologic processes, such as vowel reduction, assimilation, or deletion?
Y/N	Is there different number or placement of cross-stroke or dotted letters present in the names?	Y/N	Across a range of dialects, are the names consistently pronounced differently?
Y/N	Do the infixes of the name appear dissimilar when scripted?		
Y/N	Do the suffixes of the names appear dissimilar when scripted?		

Table 4: Moderately Similar Name Pair Checklist (i.e., combined score is $\geq 55\%$ to $\leq 69\%$).

Step 1	Review the DOSAGE AND ADMINISTRATION and HOW SUPPLIED/STORAGE AND HANDLING sections of the prescribing information (or for OTC drugs refer to the Drug Facts label) to determine if strengths and doses of the name pair overlap or are very similar. Different strengths and doses for products whose names are moderately similar may decrease the risk of confusion between the moderately similar name pairs. Name pairs that have overlapping or similar strengths or doses have a higher potential for confusion and should be evaluated further (see Step 2). Because the strength or dose could be used to express an order or prescription for a particular drug product, overlap in one or both of these components would be reason for further evaluation. For single strength products, also consider circumstances where the strength may not be expressed. For any i.e., drug products comprised of more than one active ingredient, consider whether the strength or dose may be expressed using only one of the components. To determine whether the strengths or doses are similar to your proposed product, consider the following list of factors that may increase confusion: • Alternative expressions of dose: 5 mL may be listed in the prescribing information, but the dose may be expressed in metric weight (e.g., 500 mg) or in non-metric units (e.g., 1 tsp, 1 tablet/capsule). Similarly, a strength or dose of 1000 mg may be expressed, in practice, as 1 g, or vice versa. • Trailing or deleting zeros: 10 mg is similar in appearance to 100 mg which may potentiate confusion between a name pair with moderate similarity. • Similar sounding doses: 15 mg is similar in sound to 50 mg
Step 2	Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may reduce the likelihood of confusion for moderately similar names <u>with</u> overlapping or similar strengths or doses.

	Orthographic Checklist (Y/N to each question) - Do the names begin with different first letters? Note that even when names begin with different first letters, certain letters may be confused with each other when scripted. - Are the lengths of the names dissimilar* when scripted? *FDA considers the length of names different if the names differ by two or more letters. - Considering variations in scripting of some letters (such as z and f), is there a different number or placement of upstroke/downstroke letters present in the names? - Is there different number or placement of cross-stroke or dotted letters present in the names? - Do the infixes of the name appear dissimilar when scripted? - Do the suffixes of the names appear dissimilar when scripted?	Phonetic Checklist (Y/N to each question) - Do the names have different number of syllables? - Do the names have different syllabic stresses? - Do the syllables have different phonologic processes, such vowel reduction, assimilation, or deletion? - Across a range of dialects, are the names consistently pronounced differently?
--	--	---

Table 5: Low Similarity Name Pair Checklist (i.e., combined score is $\leq 54\%$).

Names with low similarity are generally acceptable unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

Appendix B: Prescription Simulation Samples and Results

Figure 1. Exblifep Study (Conducted on July 7, 2023)

Handwritten Medication Order/Prescription	Verbal Prescription
Medication Order: <i>Exblifep 2.5grams via intravenous infusion every 8 hours</i>	Exblifep Take to clinic Dispense 6 vials
Outpatient Prescription: <i>Exblifep</i> <i>Take to clinic</i> <i>#6 vials</i>	
CPOE Study Sample (displayed as sans-serif, 12-point, bold font) Exblifep	

FDA Prescription Simulation Responses (Aggregate Report)

As of Date: 07/24/2023 12:32

Study Name: Exblifep - 2023-07-07 People Received Study: 254 People Responded: 87					
Total	24	21	22	20	87
INTERPRETATION	INPATIENT	OUTPATIENT	VOICE	CPOE	TOTAL
AXPLEFEP	0	0	1	0	1
AXPLIFEP	0	0	1	0	1
EXBLEEFEP	0	0	2	0	2
EXBLEFEP	0	0	1	0	1
EXBLEPHEP	0	0	1	0	1
EXBLIFEB	1	0	0	0	1

EXBLIFEP	23	20	2	20	65
EXBLIFEV	0	0	1	0	1
EXBRICP	0	1	0	0	1
EXFLIPA	0	0	1	0	1
EXLEAFED	0	0	1	0	1
EXLEFEP	0	0	1	0	1
EXPIVEV	0	0	1	0	1
EXPLEEVEC	0	0	1	0	1
EXPLEFEIB	0	0	1	0	1
EXPLETHA	0	0	1	0	1
EXPLETHATE	0	0	1	0	1
EXPLEVIA	0	0	1	0	1
EXPLIFA	0	0	1	0	1
EXPLIFEB	0	0	1	0	1
XBLEEFEB	0	0	1	0	1
XPLIFEP	0	0	1	0	1

Appendix C: Highly Similar Names (e.g., combined POCA score is $\geq 70\%$)

No.	Proposed name: Exblifep Established name: cefepime and enmetazobactam Dosage form: for Injection Strength(s): 2.5 grams per vial (2 grams cefepime and 0.5 grams enmetazobactam per vial) Usual Dose: 2.5 grams (cefepime 2 grams and enmetazobactam 0.5 grams) every 8 hours for 7 to 14 days	POCA Score (%)	Orthographic and/or phonetic differences in the names sufficient to prevent confusion Other prevention of failure mode expected to minimize the risk of confusion between these two names.
1.	Exblifep	100	Name is the subject of this review.
2.	Nexlizet	66	Orthographically, the names begin with different letters (E <i>versus</i> N). The prefixes ('Exb-' <i>versus</i> 'Nex-') and suffixes ('-fep' <i>versus</i> '-zet') look different. Phonetically, the third syllables ('fep' <i>versus</i> 'zet') sound different. Additionally, the product characteristics between the name pair are different. Specifically, Exblifep does not overlap with Nexlizet in dose (2.5 grams, 1.25 grams, and 0.625 grams <i>versus</i> 180 mg/10 mg or 1 tablet). Additionally, there is no numeric overlap in strength (2.5 grams per vial (2 grams/0.5 grams per vial) <i>versus</i> 180 mg/10 mg), route of administration (intravenous infusion <i>versus</i> oral), or dosage form (for injection <i>versus</i> tablet), if included on a prescription/medication order. When the aforementioned mitigations are considered in totality, we find the risk for confusion is adequately minimized in this case.

Appendix D: Moderately Similar Names (e.g., combined POCA score is $\geq 55\%$ to $\leq 69\%$) with no overlap or numerical similarity in Strength and/or Dose

No.	Name	POCA Score (%)
1.	N/A	

Appendix E: Moderately Similar Names (e.g., combined POCA score is $\geq 55\%$ to $\leq 69\%$) with overlap or numerical similarity in Strength and/or Dose

No.	Proposed name: Exblifep Established name: cefepime and enmetazobactam Dosage form: for Injection Strength(s): 2.5 grams per vial (2 grams cefepime and 0.5 grams enmetazobactam per vial) Usual Dose: 2.5 grams (cefepime 2 grams and enmetazobactam 0.5 grams) every 8 hours for 7 to 14 days	POCA Score (%)	Prevention of Failure Mode In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names
1.	(b) (4) ***	56	This name pair has sufficient orthographic and phonetic differences.
2.	Maxifed	55	This name pair has sufficient orthographic and phonetic differences.
3.	Esbriet	54	This name pair has sufficient orthographic and phonetic differences.
4.	Exforge	48	This name pair has sufficient orthographic and phonetic differences.

Appendix F: Low Similarity Names (e.g., combined POCA score is $\leq 54\%$)

No.	Name	POCA Score (%)
1.	Abilify	48
2.	Exenatide	47
3.	Cablivi	44
4.	Enalapril	36

Appendix G: Names not likely to be confused or not used in usual practice settings for the reasons described.

No.	Name	POCA Score (%)	Failure preventions
1.	Explemed	68	International product marketed in Czech Republic, Hungary, and Poland.

No.	Name	POCA Score (%)	Failure preventions
2.	Exalief	64	International product marketed in Russia. International product formerly marketed in Czech Republic, Ireland, Netherland, Poland, and Portugal.
3.	Ezoclip	64	International product marketed in Portugal.
4.	Elify EP	62	Name identified in external study. Root name, Elify, is an international product marketed in Czech Republic and Greece.
5.	Lexifen	62	Name identified in RxNorm database. Unable to find product characteristics in commonly used drug databases.
6.	Exefen-PD	61	Name identified in RxNorm database. Product is deactivated and no generic equivalents are available.
7.	Excel Pet	60	Veterinary product.
8.	AklofEP	58	International product marketed in Hungary.
9.	Ex-Pain Sleep	58	Name identified in RxNorm database. Unable to find product characteristics in commonly used drug databases.
10.	Exefen	57	Name identified in RxNorm database. Product is deactivated and no generic equivalents are available.
11.	Belifax	54	International product marketed in Greece.
12.	Exputex	54	International product marketed in Ireland.
13.	Exbol	53	International product marketed in Poland.
14.	Relifex	53	International product marketed in Denmark, Mexico, Germany, Greece, Italy, Norway, Hungary, Ireland, Philippines, and Sweden. International product formerly marketed in Brazil, Hong Kong, Poland, Thailand, Turkey, Israel, Czech Republic, Finland, United Kingdom, and Singapore.
15.	Exluton	51	International product marketed in Chile, Indonesia, Mexico, Philippines, Thailand, Brazil, Netherlands, Russia, and Venezuela. International product formerly marketed in Argentina, Belgium, Czech Republic, Finland, France, Portugal, South Africa, and Ukraine.
16.	Altifex	49	International product marketed in Denmark and Sweden. International product formerly marketed in Norway.
17.	Estrotep	49	International product marketed in France.

No.	Name	POCA Score (%)	Failure preventions
18.	Sublivac	47	International product marketed in Greece and Germany. International product formerly marketed in Netherlands.
19.	Eletop	46	International product marketed in Austria.
20.	Elinap	46	International product formerly marketed in Greece.
21.	Exoderil	46	International product marketed in Germany, Hong Kong, Austria, Czech Republic, Hungary, Indonesia, Malaysia, Poland, Russia, Turkey, and Ukraine. International product formerly marketed in Singapore, Greece, Israel, and Switzerland
22.	Ezelip	46	Name identified in external study. Unable to find product characteristics in commonly used drug databases.
23.	Eulitop	45	International product marketed in Belgium and Spain.
24.	Ezolip	45	International product marketed in Poland.
25.	Equilon	30	International product formerly marketed in the United Kingdom.
26.	Entumin	26	International product marketed in Switzerland, Italy, and Israel.

Appendix H: Names not likely to be confused due to absence of attributes that are known to cause name confusion^f.

No.	Name	POCA Score (%)
1.	Oxyblend	58
2.	Flexprofen	56
3.	Alpelisib	55
4.	Hexidip	55
5.	Hexi-Dip	55
6.	Hexi-Dip 110	55

^f Shah, M, Merchant, L, Chan, I, and Taylor, K. Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DEBORAH E MYERS
09/11/2023 04:54:03 PM

VALERIE S VAUGHAN
09/11/2023 04:56:51 PM

MISHALE P MISTRY
09/12/2023 04:38:51 PM